MRNS - マリナス・ファ―マシュ―ティカルズ (Marinus Pharmaceuticals Inc.) マリナス・ファ―マシュ―ティカルズ

 MRNSのチャート


 MRNSの企業情報

symbol MRNS
会社名 Marinus Pharmaceuticals Inc (マリナス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Marinus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate ganaxolone is a modulator being developed in various dose forms including intravenous oral capsule and oral liquid intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications including adjunctive or add-on therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome and PCDH19 pediatric epilepsy.   マリナス・ファ―マシュ―ティカルズは精神神経疾患の治療薬の開発と商品化に焦点を置く米国のバイオ医薬品会社。成人てんかん、PCDH119遺伝子変異てんかん、脆弱X染色体症候群の治療用合成ニュ―ロステロイドganaxolone(経口剤)の治験を行う。また、急性発作患者に対するganaxoloneの点滴剤の開発を行う。   Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety potential. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 3 trial in refractory status epilepticus, Phase 2 trial in tuberous sclerosis complex and a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy.
本社所在地 170 N. Radnor Chester Rd. Suite 250 Radnor PA 19087 USA
代表者氏名 Christopher M. Cashman Christopher M. Cashman
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 484-801-4670
設立年月日 37834
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 16人
url www.marinuspharma.com
nasdaq_url https://www.nasdaq.com/symbol/mrns
adr_tso
EBITDA EBITDA(百万ドル) -24.66500
終値(lastsale) 7.37
時価総額(marketcap) 298669345.81
時価総額 時価総額(百万ドル) 231.80310
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 185.43410
当期純利益 当期純利益(百万ドル) -24.41100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Marinus Pharmaceuticals Inc revenues was not reported. Net loss increased 55% to $15.5M. Higher net loss reflects Other Research and Development increase of 72% to $10.3M (expense) Stock-based Compensation in SGA increase of 68% to $1.6M (expense) Stock-based Compensation in R&D increase from $370K to $816K (expense).

 MRNSのテクニカル分析


 MRNSのニュース

   Marinus Pharmaceuticals (MRNS) Investor Presentation - Slideshow  2021/05/26 18:52:31 Seeking Alpha
   35 Graham Formula Value Dogs Sport 26 Ideal June Dividend Payers  2021/05/26 17:33:52 Seeking Alpha
   Wells Fargo's status as a top lender to US restaurants is in jeopardy after MUFG snared 8 of its prized bankers to beef up its own division  2021/05/26 16:51:14 Business Insider
Summary List Placement Wells Fargo has lost what was effectively its entire team of restaurant financiers – threatening its stance as one of the strongest lenders to restaurant chains. Eight bankers, including Nick Cole who heads Wells' restaurant group, are joining MUFG in June, as the Japanese lender doubles down on opportunities within the restaurant space. Lending to fast, casual food companies like Burger King and Chipotle have become lucrative opportunities for banks as they've thrived throughout the pandemic as consumers opted for quick solutions that avoid dine-in crowds. Wells was the top lender to US restaurants in 2020 and has been in the top or second spot on the leaderboard since at least 2016, according to data from Refinitiv. However, it remains hamstrung by a fake accounts scandal unearthed in 2016 that forced it to revamp risk management and pay billions of dollars in penalties. In February, Wells' proposal to improve its governance and risk management processes was accepted by the US Federal Reserve, indicating it's progressing toward having its $2 trillion asset cap lifted.
   Goldman Sachs shares 11 stocks to buy as the global economy recovery gains steam and companies with high international revenues crush their domestic-facing peers  2021/05/26 14:45:00 Business Insider
Summary List Placement Market leadership has flipped from US-focused stocks to international stocks and back again in the last 14 months, and Goldman Sachs says the baton will soon get passed once more. The US reopening trade has been a powerful catalyst for domestically oriented stocks thanks to the strength of the economy and the speedy vaccine rollout. But Chief US Equity Strategist David Kostin says that potential is increasingly priced in. "Stocks with high domestic sales exposure will likely lag those with high foreign sales exposure during the coming months as the pace of global economic recovery surpasses that of the US," he wrote in a note to clients. That's how the market looked for much of 2020 after the COVID crash, although the effect faded this February as the US economy regained strength. But Kostin says that's now priced in, to an extent. "The structural decline of the US dollar and the acceleration of global growth relative to the US should benefit global-facing US companies relative to domestic-facing stocks," Kostin wrote.
   Marinus Pharmaceuticals (MRNS) Investor Presentation - Slideshow  2021/05/26 18:52:31 Seeking Alpha
   35 Graham Formula Value Dogs Sport 26 Ideal June Dividend Payers  2021/05/26 17:33:52 Seeking Alpha
   Wells Fargo's status as a top lender to US restaurants is in jeopardy after MUFG snared 8 of its prized bankers to beef up its own division  2021/05/26 16:51:14 Business Insider
Summary List Placement Wells Fargo has lost what was effectively its entire team of restaurant financiers – threatening its stance as one of the strongest lenders to restaurant chains. Eight bankers, including Nick Cole who heads Wells' restaurant group, are joining MUFG in June, as the Japanese lender doubles down on opportunities within the restaurant space. Lending to fast, casual food companies like Burger King and Chipotle have become lucrative opportunities for banks as they've thrived throughout the pandemic as consumers opted for quick solutions that avoid dine-in crowds. Wells was the top lender to US restaurants in 2020 and has been in the top or second spot on the leaderboard since at least 2016, according to data from Refinitiv. However, it remains hamstrung by a fake accounts scandal unearthed in 2016 that forced it to revamp risk management and pay billions of dollars in penalties. In February, Wells' proposal to improve its governance and risk management processes was accepted by the US Federal Reserve, indicating it's progressing toward having its $2 trillion asset cap lifted.
   Goldman Sachs shares 11 stocks to buy as the global economy recovery gains steam and companies with high international revenues crush their domestic-facing peers  2021/05/26 14:45:00 Business Insider
Summary List Placement Market leadership has flipped from US-focused stocks to international stocks and back again in the last 14 months, and Goldman Sachs says the baton will soon get passed once more. The US reopening trade has been a powerful catalyst for domestically oriented stocks thanks to the strength of the economy and the speedy vaccine rollout. But Chief US Equity Strategist David Kostin says that potential is increasingly priced in. "Stocks with high domestic sales exposure will likely lag those with high foreign sales exposure during the coming months as the pace of global economic recovery surpasses that of the US," he wrote in a note to clients. That's how the market looked for much of 2020 after the COVID crash, although the effect faded this February as the US economy regained strength. But Kostin says that's now priced in, to an extent. "The structural decline of the US dollar and the acceleration of global growth relative to the US should benefit global-facing US companies relative to domestic-facing stocks," Kostin wrote.
   The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link  2021/03/10 12:25:58 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 9) Amneal Pharmaceuticals, Inc. (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC ) ( announced a new-gen multi-cancer detection sensor) Axonics Modulation Technologies, Inc. (NASDAQ: AXNX ) Bausch Health Companies Inc. (NYSE: BHC ) (issued a pipeline update at a conference) Bolt Biotherapeutics, Inc. (NASDAQ: BOLT ) Cullinan Oncology, Inc. (NASDAQ: CGEM ) Five Prime Therapeutics, Inc. (NASDAQ: FPRX ) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS ) (reacted to its fourth-quarter results) Second Sight Medical Products, Inc. (NASDAQ: EYES ) Silverback Therapeutics, Inc. (NASDAQ: SBTX ) Surmodics, Inc. (NASDAQ: SRDX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 9) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) (moved lower in reaction to FDA communication regarding deficiencies in its regulatory application for dementia drug) Immunocore Holdings plc (NASDAQ: IMCR ) Stocks In Focus MediciNova Gets BARDA Contract to Study MN-166 For Chlorine Gas-induced Lung Damage MediciNova, Inc. (NASDAQ: MNOV ) said it has partnered with the BARDA to repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome and acute lung injury.
   Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2021/02/12 21:01:00 Business Wire
RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MRNS--Marinus today announced the grant of inducement awards to five new employees.
   Marinus Enrolls First Patient in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status Epilepticus  2021/01/26 12:01:00 Business Wire
RADNOR, Pa.--(BUSINESS WIRE)-- #Ceribell--Marinus Pharma announces the first refractory status epilepticus patient enrolled in its Phase 3 RAISE study.
   Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in CDKL5 Deficiency Disorder (CDD)  2021/01/13 12:01:00 Business Wire
RADNOR, Pa.--(BUSINESS WIRE)-- #CDD--Marinus received a positive response from the FDA on sufficiency of Marigold Study data to support filing of NDA for the use of ganaxolone in CDD.
   Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference  2021/01/06 12:02:00 Business Wire
RADNOR, Pa.--(BUSINESS WIRE)-- #HCWBioConnect--Marinus management will participate in the 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect 2021 Conference.

 関連キーワード  (医薬品 米国株 マリナス・ファ―マシュ―ティカルズ MRNS Marinus Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)